vidarabine has been researched along with Febrile Neutropenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheah, R; Dendle, C; Gregory, G; Mohan, B; Tey, A | 1 |
| Ali, S; Olszewski, AJ; Shafqat, H | 1 |
2 other study(ies) available for vidarabine and Febrile Neutropenia
| Article | Year |
|---|---|
Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Multiple, Fungal; Drug Substitution; Fatal Outcome; Febrile Neutropenia; Female; Filgrastim; Fluconazole; Humans; Immunocompromised Host; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperacillin, Tazobactam Drug Combination; Purines; Quinazolinones; Recurrence; Rituximab; Scedosporium; Triazoles; Valacyclovir; Vidarabine | 2020 |
Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Outcome Assessment, Health Care; Prednisone; Rituximab; SEER Program; Survival Analysis; United States; Vidarabine; Vincristine | 2015 |